Adenocarcinoma of the prostatePopulation-based cancer registrationAfricaSurvivalCancer surveillanceWe found poor survival of SSA prostatic tumor patients, as well as high proportions of late stage presentation, which are associated with inferior outcome. This calls for investment in health-care systems and...
MP05-05 LONG-TERM OUTCOMES OF MEN WITH STAGE PT3B PROSTATE CANCER DIAGNOSED BY SEMINAL VESICLE BIOPSY AND TREATED BY BRACHYTHERAPY AND EXTERNAL BEAM IRRADIATION Patients who present with localized and locally advanced prostate cancer may be candidates for prostate brachytherapy. We evaluated the treatme...
Objective: The detrimental effect of unmarried marital status on stage and survival has been confirmed in several malignancies. We set to test whether this applied to patients diagnosed with prostate cancer (PCa) treated with radical prostatectomy (RP). Methods: We identified 163,697 non-metastatic...
Survival paradox between stage IIB/C and stage IIIA colon cancer: is it time to revise the American Joint Committee on Cancer TNM system? Introduction A survival paradox between T4N0 (Stage IIB/IIC) and Stage IIIA colon cancer exists, even after adjusting for adequate lymph node (LN) retriev...
OBJECTIVES To use self-assigned ethnicity to examine patterns of incidence, stage, treatment and survival in patients with prostate cancer in South-east ... RH Jack,EA Davies,Henrik Mller - 《Bju International》 被引量: 39发表: 2010年 Racial and ethnic disparities in cancer survival by neighbo...
While the 5-year survival rate for local and regional prostate cancer is nearly 100%, it decreases dramatically for advanced tumours. Accessibility to health care is an important factor for cancer prognosis. The U.S. Military Health System (MHS) provides universal health care to its beneficiaries...
1 Currently, the 5-year survival rates for stage III NSCLC range from approximately 36% for stage IIIA to 26% for stage IIIB to 13% for stage IIIC.3 Although the past 2 decades saw an abundance of targeted agents and immunotherapies emerge for metastatic NSCLC, progress in locally advanced...
In the past, the life expectancy of men with metastaticprostate cancerwas 2-3 years. Butwith advancements in medicine and care, the life expectancy of men with metastatic prostatecancerhas increased to about 5-6 years. The 5-year survival rate of metastatic prostate canceris 28%, which is ...
2000 Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment - JE, SA, et al. () Citation Context ...and IGFBP-3 genotype BMI (kg/m2) Genotype (n) Mean IGFBP-3 6 SE (ng/mL) P valuea ,23 AA (19) 3123 6 128 AC (...
For prostate cancer, presentation at stage 2 (Po0.001) and unknown stage (Po0.05) is more common for the least deprived, whereas presentation at stages 3 (Po0.05) and 4 (Po0.001) is more common in the most deprived. Variation in relative survival. Table 3 shows relative survival and age...